Table III.
Complications | LABA + LAMA group (n=13) (%) | LAMA (n=19) (%) | P-value |
---|---|---|---|
Pulmonary complications | 2 (15) | 8 (42) | 0.109 |
Pneumonia | 0 (0) | 5 (26) | 0.044 |
Acute respiratory failure | 0 (0) | 2 (11) | 0.227 |
Chronic respiratory failure | 2 (15) | 6 (32) | 0.299 |
Cardiovascular complications | 3 (23) | 3 (16) | 0.604 |
Atrial fibrillation | 2 (15) | 3 (16) | 0.975 |
Values are shown as numbers (%). LAMA, long-acting muscarinic antagonist; LABA, long-acting β2-agonist.